Veltassa

Vifor Fresenius Medical Care Renal Pharma France,100-101 Terrasse Boieldieu,Tour Franklin La Defense 8,Paris La Defense,Cedex 92042,Paris,France🇪🇺 European Union

EMA Page

Authorised Date: Jul 19, 2017
Approval ID: dc5e0e9a459911e6
Products: 1 listed
Opinion Adopted: N/A

Overview Summary

<p>Veltassa is a medicine used for treating adults and adolescents aged 12 years and above with high levels of potassium in the blood (hyperkalaemia). Hyperkalaemia can cause serious heart problems and muscle weakness.</p><p>Veltassa contains the active substance patiromer.</p>

Therapeutic & Classification

Therapeutic Indication

<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Veltassa is indicated for the treatment of hyperkalaemia in adults and adolescents aged 12 to 17 years.</p> </div>

Therapeutic Area (MeSH)

Hyperkalemia

ATC Code

V03AE09

ATC Item

N/A

Pharmacotherapeutic Group

Drugs for treatment of hyperkalemia and hyperphosphatemia

Active Substances

Active Substance (Summary)

patiromer sorbitex calcium

INN / Common Names

patiromer

Active Substance Details

Substance	CAS	Monograph
patiromer sorbitex calcium	N/A	patiromer sorbitex calcium

Quick Info

Approval IDdc5e0e9a459911e6

Product NumberN/A

StatusAuthorised

Authorised DateJul 19, 2017

Opinion AdoptedN/A

Revision #N/A

Names & Aliases

EMA Name

Veltassa

Medicine Name

Veltassa

Aliases

N/A

Regulatory Flags

Orphan medicineUnknown

Generic medicineUnknown

BiosimilarUnknown

Conditional approvalUnknown

Exceptional circumstancesUnknown

Accelerated assessmentUnknown

Additional monitoringUnknown

Advanced therapyUnknown

Source Links

EMA Source

No risk management plan link.

Back to EMA Approvals